Insmed Incorporated – NASDAQ:INSM
Insmed Incorporated stock price today
$127.42
+57.81
+83.05%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Insmed Incorporated stock price monthly change
-9.26%
month
Insmed Incorporated stock price quarterly change
-9.26%
quarter
Insmed Incorporated stock price yearly change
+120.01%
year
Insmed Incorporated key metrics
Market Cap | 12.30B |
Enterprise value | 2.34B |
P/E | -4.22 |
EV/Sales | 9.54 |
EV/EBITDA | -5.21 |
Price/Sales | 9.12 |
Price/Book | 25.45 |
PEG ratio | 5.45 |
EPS | -5.23 |
Revenue | 315.49M |
EBITDA | -671.57M |
Income | -746.89M |
Revenue Q/Q | 15.77% |
Revenue Y/Y | 22.53% |
Profit margin | -196.26% |
Oper. margin | -191.12% |
Gross margin | 77.53% |
EBIT margin | -191.12% |
EBITDA margin | -212.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInsmed Incorporated stock price history
Insmed Incorporated stock forecast
Insmed Incorporated financial statements
| Jun 2023 | 77.22M | -244.80M | -316.99% |
|---|---|---|---|
| Sep 2023 | 79.07M | -158.93M | -201% |
| Dec 2023 | 83.69M | -186.06M | -222.31% |
| Mar 2024 | 75.5M | -157.09M | -208.07% |
| 2025 | 516.93M | -672.68M | -130.13% |
|---|---|---|---|
| 2026 | 901.46M | -410.94M | -45.59% |
| 2027 | 1.49B | 30.71M | 2.06% |
| 2028 | 2.12B | 380.57M | 17.88% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1439139000 | 1.59B | 110.82% |
|---|---|---|---|
| Sep 2023 | 1324873000 | 1.61B | 121.84% |
| Dec 2023 | 1329837000 | 1.66B | 124.96% |
| Mar 2024 | 1159095000 | 1.62B | 140.1% |
| Jun 2023 | -122.79M | -274.15M | 44.32M |
|---|---|---|---|
| Sep 2023 | -136.33M | 7.14M | 1.24M |
| Dec 2023 | -130.81M | 1.80M | 123.26M |
| Mar 2024 | -184.03M | 295.32M | 3.02M |
Insmed Incorporated alternative data
| Sep 2023 | 736 |
|---|---|
| Oct 2023 | 736 |
| Nov 2023 | 736 |
| Dec 2023 | 736 |
| Jan 2024 | 736 |
| Feb 2024 | 736 |
| Mar 2024 | 912 |
| Apr 2024 | 912 |
| May 2024 | 912 |
| Jun 2024 | 912 |
| Jul 2024 | 912 |
Insmed Incorporated other data
100.00%
0.00%
of INSM is owned by hedge funds
208
+8
125.14M
+2.01M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 125386 |
| May 2024 | 0 | 525422 |
| Jun 2024 | 0 | 76195 |
| Aug 2024 | 0 | 97539 |
| Sep 2024 | 0 | 254853 |
| Dec 2024 | 0 | 51160 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LEWIS WILLIAM director, officer.. | Common Stock | 18,750 | $22.76 | $426,750 | ||
Sale | LEWIS WILLIAM director, officer.. | Common Stock | 13,162 | $69.65 | $916,733 | ||
Sale | LEWIS WILLIAM director, officer.. | Common Stock | 5,588 | $70.52 | $394,066 | ||
Option | LEWIS WILLIAM director, officer.. | Common Stock | 6,830 | $10.85 | $74,106 | ||
Sale | LEWIS WILLIAM director, officer.. | Common Stock | 5,240 | $69.71 | $365,280 | ||
Sale | LEWIS WILLIAM director, officer.. | Common Stock | 1,590 | $70.61 | $112,270 | ||
Option | LEWIS WILLIAM director, officer.. | Stock Option (right to buy) | 6,830 | $10.85 | $74,106 | ||
Option | LEWIS WILLIAM director, officer.. | Stock Option (right to buy) | 18,750 | $22.76 | $426,750 | ||
Option | LEWIS WILLIAM director, officer.. | Common Stock | 18,750 | $22.76 | $426,750 | ||
Sale | LEWIS WILLIAM director, officer.. | Common Stock | 11,504 | $72.58 | $834,960 |
| Patent |
|---|
Application Filling date: 10 Jun 2021 Issue date: 5 May 2022 |
Application Filling date: 10 Mar 2021 Issue date: 20 Jan 2022 |
Application Filling date: 12 Feb 2021 Issue date: 2 Dec 2021 |
Application CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS Filling date: 16 Jul 2019 Issue date: 21 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. William H. Lewis J.D., M.B.A. (1969) Pres, Chief Executive Officer & Chairman | $1,190,000 |
Dr. Martina Flammer M.B.A., M.D. (1964) Chief Medical Officer | $934,410 |
| Mr. Roger Adsett (1969) Chief Operating Officer | $793,900 |
| Ms. Christine A. Pellizzari J.D. (1968) Consultant | $732,850 |
Ms. Sara M. Bonstein MBA (1981) Chief Financial Officer | $697,720 |
What Next For Liquidia After Launch?
Liquidia: Competitor Insmed's Stunning PAH Data Arrives At Precisely The Wrong Time
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
Insmed: Company Presses On With Further POC PAH Treatment Data
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Insmed: Poised For Transformation Beyond ARIKAYCE
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
-
What's the price of Insmed Incorporated stock today?
One share of Insmed Incorporated stock can currently be purchased for approximately $127.42.
-
When is Insmed Incorporated's next earnings date?
Unfortunately, Insmed Incorporated's (INSM) next earnings date is currently unknown.
-
Does Insmed Incorporated pay dividends?
No, Insmed Incorporated does not pay dividends.
-
How much money does Insmed Incorporated make?
Insmed Incorporated has a market capitalization of 12.30B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.39% to 305.21M US dollars.
-
What is Insmed Incorporated's stock symbol?
Insmed Incorporated is traded on the NASDAQ under the ticker symbol "INSM".
-
What is Insmed Incorporated's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Insmed Incorporated?
Shares of Insmed Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Insmed Incorporated's key executives?
Insmed Incorporated's management team includes the following people:
- Mr. William H. Lewis J.D., M.B.A. Pres, Chief Executive Officer & Chairman(age: 56, pay: $1,190,000)
- Dr. Martina Flammer M.B.A., M.D. Chief Medical Officer(age: 61, pay: $934,410)
- Mr. Roger Adsett Chief Operating Officer(age: 56, pay: $793,900)
- Ms. Christine A. Pellizzari J.D. Consultant(age: 57, pay: $732,850)
- Ms. Sara M. Bonstein MBA Chief Financial Officer(age: 44, pay: $697,720)
-
How many employees does Insmed Incorporated have?
As Jul 2024, Insmed Incorporated employs 912 workers.
-
When Insmed Incorporated went public?
Insmed Incorporated is publicly traded company for more then 25 years since IPO on 1 Jun 2000.
-
What is Insmed Incorporated's official website?
The official website for Insmed Incorporated is insmed.com.
-
Where are Insmed Incorporated's headquarters?
Insmed Incorporated is headquartered at 700 US Highway 202/206, Bridgewater, NJ.
-
How can i contact Insmed Incorporated?
Insmed Incorporated's mailing address is 700 US Highway 202/206, Bridgewater, NJ and company can be reached via phone at +90 89779900.
Insmed Incorporated company profile:
Insmed Incorporated
insmed.comExchange:
NASDAQ
Full time employees:
912
Industry:
Biotechnology
Sector:
Healthcare
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
700 US Highway 202/206
Bridgewater, NJ 08807
Bridgewater, NJ 08807
CIK: 0001104506
ISIN: US4576693075
CUSIP: 457669307
